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Abstract34
Tumours depend on altered rates of protein synthesis for growth and survival, suggesting 35
that mechanisms controlling mRNA translation may be exploitable for therapy. Here, we 36
show that loss of APC, which occurs almost universally in colorectal tumours, strongly 37
enhances the dependence on the translation initiation factor eIF2B5. Depletion of eIF2B5 38
induces an integrated stress response and enhances translation of MYC via an internal 39
ribosomal entry site. This perturbs cellular amino acid and nucleotide pools and strains 40
energy resources and causes MYC-dependent apoptosis. eIF2B5 limits MYC expression and 41
prevents apoptosis in APC-deficient murine and patient-derived organoids and in APC-42
deficient murine intestinal epithelia in vivo. Conversely, the high MYC levels present in APC-43
deficient cells induce phosphorylation of eIF2α via the GCN2 and PKR kinases. 44
Pharmacological inhibition of GCN2 phenocopies eIF2B5 depletion and has therapeutic 45
efficacy in tumour organoids, demonstrating that a negative MYC/eIF2α feedback loop 46
constitutes a targetable vulnerability of colorectal tumours. 47
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Introduction48
Overall rates of cellular protein synthesis are regulated by extracellular and cell-intrinsic 49
signals. Specifically, recognition of the mRNA cap structure by eIF4F as well as binding and 50
recycling of the ternary complex (TC) are tightly controlled steps during translation initiation 51
[1, 2]. In response to stress signals, eIF2α, a component of the TC, is phosphorylated [3]. 52
This enhances its affinity for eIF2B, which sequesters phosphorylated eIF2α into an inactive 53
complex, and disrupts TC formation [4-6]. Reduction in TC levels inhibits global translation 54
initiation, but enhances translation of stress-responsive mRNAs via the integrated stress 55
response (ISR) [3]. 56
Virtually all colorectal cancers (CRC) harbor activating mutations in the WNT signaling 57
pathway. Most frequently, this is due to deletion or loss-of-function mutations of the APC58
tumour suppressor [7], leading to an upregulation of the transcription factor MYC [8]. 59
Restoration of Apc or deletion of Myc ablates tumourigenesis in mouse models of CRC [9, 60
10]. MYC induces transcription of genes encoding proteins of the translation machinery [7], 61
and enhances global protein synthesis [8, 11-13]. Interfering with translation initiation or the 62
mTOR-eEF2K axis controlling translational elongation is tolerated by normal tissues but 63
prevents CRC growth, arguing that CRC depends on enhanced protein synthesis [1, 11, 14-64
16].65
Here, we searched for specific dependencies of APC-deficient CRCs. Starting from an 66
unbiased genetic screen, we identified a negative feedback loop, in which deregulated MYC 67
expression and global translation in APC-deficient cells induce phosphorylation of eIF2α,68
which limits protein synthesis. Using mouse tumour models as well as murine and patient-69
derived organoids, we validated this dependency. Disrupting this circuit either genetically or 70
by small molecule inhibitors of eIF2α kinases has therapeutic efficacy in APC-deficient 71
tumours.  72
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Results73
Restoration of APC expression suppresses translation and anchorage-independent growth 74
To identify genes that are essential in APC-deficient cells, we engineered SW480 cells, 75
harbouring truncating mutations in both APC alleles, to express full-length APC in a 76
doxycycline-inducible manner (SW480TetOnAPC) (Fig. 1a and Extended Data 1a,b). We 77
designate these cells APC-deficient (APCdef) in the absence and APC-restored (APCres) in 78
the presence of doxycycline. In APCres cells, β-catenin protein levels and mRNA expression 79
of MYC, DKK1 and AXIN2 were significantly downregulated (Fig. 1a,b,c and Extended Data 80
1b,c). Gene set enrichment analysis (GSEA) of RNA-sequencing data showed that induction 81
of APC represses multiple WNT- and MYC-regulated genes (Fig. 1d), including genes 82
encoding proteins involved in translation (Fig. 1d and Supplementary Table 1) [17-20]. 83
Consistent with these data and previous observations, global protein synthesis was 84
enhanced in APCdef cells (Fig. 1e) [11]. Restoration of APC did not affect cell growth in two-85
dimensional culture conditions and did not induce apoptosis (Fig. 1f, and Extended Data 1d). 86
In contrast, the number and size of APCres colonies growing in an anchorage-independent 87
manner, a hallmark of oncogenic transformation [21], were markedly reduced (Fig. 1g,h,i) 88
[22].89
90
APC-deficient CRC cells depend on physiological eIF2B5 levels 91
To identify genes required for the growth of APCdef, but not of APCres cells, we performed a 92
dropout screen and infected SW480TetOnAPC cells with a lentiviral shRNA library targeting 93
5,000 potentially druggable genes encoding translation initiation and elongation factors as 94
well as ribosomal proteins (Extended Data 1e,f). For each shRNA, relative enrichment or 95
depletion after day 3 and day 15 of ethanol or doxycycline treatment was determined. 96
Twenty-one shRNAs targeting luciferase, included as negative controls, were not selected 97
against during growth of either APCdef or APCres cells (Extended Data 1g). In contrast, four 98
out of five shRNAs targeting PSMB2, encoding an essential component of the proteasome, 99
led to growth disadvantage in both APCdef and APCres cells (Extended Data 1h). Using a two-100
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fold difference in representation between APCdef and APCres cells at day 15, but not at day 3, 101
we filtered for potential hits (FDR < 0.05). From these, we recovered nine genes that were 102
targeted by at least two shRNAs (Extended Data 1i and Supplementary Table 2). Among 103
them were shRNAs targeting BCL2L1, which has previously been shown to be required for 104
growth of cells with activating β-catenin mutations [23]. Notably, four out of five shRNAs 105
targeting EIF2B5 were depleted specifically in APCdef cells, and showed the greatest 106
difference in shRNA representation (Fig. 2a). Consistent with recovery as a hit, eIF2B5 107
depletion by an shRNA, used in the screen, suppressed growth of APCdef cells, but had only 108
minor effects on APCres cells (Fig. 2b,c), despite similar knockdown efficiency (Fig. 2d,e). 109
eIF2B5 depletion in APCdef cells, but not in APCres cells, significantly increased the 110
percentage of annexin V/PI-positive cells and the percentage of cells with a subG1 DNA 111
content (Fig. 2f and Extended Data 2a). 112
113
Using a series of four shRNAs with different knockdown efficacy (Extended Data 2b), we 114
established that differential apoptosis induction in APCdef and APCres cells correlated with the 115
degree of eIF2B5 depletion (Extended Data 2c). Strong knockdown elicited by shEIF2B5 #1 116
potently induced apoptosis in APCdef, but also to some degree in APCres cells. Moderate 117
knockdown by shEIF2B5 #3 induced apoptosis in APCdef, but had no effect on APCres cells. 118
Weak knockdown (shEIF2B5 #2, #4) induced little or no apoptosis in APCdef and APCres cells. 119
To validate that apoptosis is an on-target effect, we overexpressed an shRNA-resistant HA-120
tagged eIF2B5 (eIF2B5mut-HA). Neither shEIF2B5 #1 nor #3 depleted HA-tagged 121
exogenous eIF2B5, although they are functional since they reduced expression of 122
endogenous eIF2B5 (Extended Data 2d,e). Accordingly, we observed no apoptosis in cells 123
expressing eIF2B5mut-HA (Extended Data 2f). Finally, eIF2B5 depletion strongly suppressed 124
growth of APC-deficient HT29 cells, but had a much weaker effect in APC-proficient HCT116 125
cells (Fig. 2g,h and Extended Data 2g). 126
127
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Notably, APCdef and APCres cells express comparable eIF2B5 protein levels despite increased 128
EIF2B5 mRNA levels in APCdef relative to APCres cells (Fig. 2d,e). Datasets from human 129
CRCs show a moderate increase in EIF2B5 mRNA in CRC relative to normal tissue 130
(Extended Data 2h). Histopathologic staining of human CRC samples revealed an enhanced 131
eIF2B5 expression in tumours relative to mucosa (Fig. 2i). We concluded that physiological 132
levels of eIF2B5 are required to suppress apoptosis in APC-deficient cells. 133
134
eIF2B5 controls translation initiation and limits global protein synthesis 135
eIF2B5 is the catalytic subunit of the decameric eIF2B complex [4, 24, 25], which is the 136
guanine nucleotide exchange factor (GEF) for eIF2 that replaces GDP by GTP and enables 137
binding of initiator methionyl transfer RNA (Met-tRNAi) to eIF2 (TC formation) [24, 26]. 138
Accordingly, eIF2B5 depletion caused a relative increase in free 40S and 60S ribosomal 139
subunits and a decrease in polysomal fractions (Fig. 3a and Extended Data 3a). To pinpoint 140
the effect on translation initiation, we blocked the first translation elongation step by addition 141
of harringtonine [27]. This led to an expected increase in 40S, 60S, and 80S monosomes 142
and showed that eIF2B5 depletion strongly reduced the amount of 80S monosomes 143
consistent with its effect on TC formation (Fig. 3a). Surprisingly, eIF2B5 knockdown elicited 144
an increase in overall protein synthesis in both APCdef and APCres cells (Fig. 3b). This 145
increase correlated with the degree of eIF2B5 knockdown (Extended Data 2b and 3b). In 146
CRC cells, inhibition of initiation can be compensated by an increase in translation elongation 147
driven via inhibition of eEF2K by S6K1 [11]. Accordingly, depletion of eIF2B5 strongly 148
activated S6K1 in APCdef cells (Extended Data 3c). 149
150
Consistent with previous findings, eIF2α and its phosphorylated form are upregulated in 151
tumour tissue [28] (Fig. 3c). In addition, eIF2B binds p-eIF2α with high affinity and 152
antagonizes dephosphorylation and activation of eIF2α by PP1 [29]. Depletion of eIF2B5 led 153
to dephosphorylation of eIF2α at S51, readily detectable in APCdef cells, while the effect in 154
APCres cells was more variable (Fig. 3d and Extended Data 3d). To determine whether 155
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eIF2B5 limits PP1 binding to eIF2α, we immunoprecipitated eIF2α. Depletion of eIF2B5 156
strongly enhanced association of PP1 with eIF2α in APCdef, but much less so in APCres cells 157
(Fig. 3e). This mechanism is expected to reduce the sensitivity of translation initiation to 158
inhibition by stress-related kinases. 159
160
Depletion of eIF2B5 causes MYC-driven apoptosis 161
To understand why eIF2B5 depletion causes apoptosis specifically of APCdef cells, we 162
performed ribosome profiling of APCdef and APCres cells to investigate a potential shift in the 163
spectrum of translated mRNAs [30, 31]. We did not observe any differences in global 164
ribosome association of mRNAs between eIF2B5-depleted APCdef and APCres cells 165
(Extended Data 3e and Supplementary Table 3). However, gene ontology analysis of 166
ribosome-associated mRNAs revealed an enrichment of mRNAs associated with stress 167
response and apoptotic signaling pathways upon eIF2B5 knockdown in APCdef, but less in 168
APCres cells (Extended Data 3f). This is consistent with observations that a reduction in TC 169
formation induces an ISR resulting in a bypass of upstream open reading frames (uORFs) 170
present in stress-responsive mRNAs such as that of the transcription factor ATF4 [2]. Indeed, 171
inactivating mutations in eIF2B subunits in yeast lead to the induction of the ISR [32]. 172
Accordingly, eIF2B5 knockdown induced ATF4 protein expression as well as enrichment of a 173
consensus ATF4 target gene signature including DDIT3, ATF3 and ATF6, in APCdef cells and 174
this response correlates with the degree of eIF2B5 knockdown (Fig. 3f,g, Extended Data 3g 175
and Supplementary Table 4). 176
177
Enhanced translation and defects in protein folding in the endoplasmic reticulum can activate 178
two other stress signaling pathways, mediated by IRE1α and ATF6, as part of the unfolded 179
protein response (UPR) [33]. Notably, while APC loss activated both the ISR and IRE1α as 180
well as ATF6, evidenced by expression of UPR-associated genes (spliced XBP1, GRP78181
and unspliced XBP1), additional eIF2B5 depletion induced only the ISR (Extended Data 3h,i) 182
[34].183
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184
ATF4 controls transcription of multiple stress-related genes, including GADD34 and ATF3,185
both of which were induced upon eIF2B5 knockdown in APCdef, but not in APCres cells (Fig. 186
3h and Extended Data 3i). ATF3 is important for CHOP expression [35] and CHOP can drive 187
apoptosis, eliminating cells after prolonged stress [36]. eIF2B5 depletion in APCdef cells 188
induced CHOP expression to a similar extent as exposure to tunicamycin (Extended Data 189
4a), which blocks protein glycosylation and is an established inducer of an ISR [36]. These 190
responses were attenuated in APCres cells (Extended Data 4a). siRNA-mediated CHOP 191
knockdown abolished its upregulation after eIF2B5 depletion in APCdef cells, but had only 192
minor effects on the apoptotic response after eIF2B5 depletion (Extended Data 4b,c). 193
194
APC loss strongly enhances expression of MYC mRNA [9]. Since high MYC levels induce 195
apoptosis [37], we tested whether MYC expression is differentially regulated after eIF2B5196
knockdown. Upon eIF2B5 knockdown in APCdef cells, MYC protein levels were markedly 197
upregulated, while MYC mRNA levels and protein stability remained unaltered (Fig. 4a and 198
Extended Data 4d,e). MYC protein levels were also induced by shEIF2B5 #1, but not by 199
shEIF2B5 #4 (Extended Data 4f,g). Similarly, MYC is upregulated after eIF2B5 knockdown in 200
APC-deficient HT29 cells, but not in APC-proficient HCT116 cells (Extended Data 4h). 201
Immunoprecipitation of 35S-methionine pulse-labelled MYC showed that eIF2B5 depletion 202
enhanced MYC translation in APCdef cells (Fig. 4b). In apoptotic cells, translation of MYC is 203
enhanced via an internal ribosomal entry site (IRES) [38, 39]. A specific inhibitor of MYC 204
IRES-dependent translation, cymarine [40], decreased basal MYC expression and abolished 205
its upregulation in response to eIF2B5 depletion in APCdef cells , but had no effect on two 206
other short-lived proteins (Cyclin E, c-Fos) (Fig. 4c and Extended Data 5a). Furthermore, 207
deleting an internal part of the MYC IRES by CRISPR/Cas9 abolished MYC induction upon 208
eIF2B5 knockdown (Extended Data 5b,c,d). We concluded that depletion of eIF2B5 209
enhances IRES-dependent translation of MYC. 210
211
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Depletion of MYC strongly reduced induction of apoptosis in response to eIF2B5 depletion in 212
APCdef cells (Fig. 4d,e). It also decreased basal CHOP levels and compromised CHOP, 213
ATF3 and GADD34 induction upon eIF2B5 knockdown (Fig. 4d and Extended Data 5e). We 214
concluded that eIF2B5 downregulation increases MYC translation in APCdef cells, causing 215
apoptosis. Since MYC mRNA and the ISR levels, which enhance MYC IRES translation, are 216
lower in APCres cells, eIF2B5 depletion does not cause a similar MYC upregulation in these 217
cells. 218
219
To understand how deregulation of protein synthesis and MYC expression contribute to 220
apoptosis, we determined intracellular amino acid pools. Knockdown of eIF2B5 significantly 221
reduced alanine, aspartate and glutamate levels (Fig. 5a). APC restoration or MYC depletion 222
alleviated the effects of eIF2B5 depletion on aspartate and glutamate levels. Both amino 223
acids are precursors for nucleotide synthesis, a highly energy-demanding process [41]. The 224
corresponding biosynthetic enzymes are encoded by MYC target genes and several are 225
induced following APC loss (Fig. 5b) [42]. Intriguingly, eIF2B5 depletion decreased tri-226
phosphorylated nucleotides in APCdef cells, which was lessened or abolished by APC 227
restoration, indicative of a reduction in cellular energy charge (Fig. 5c). Consistent with these 228
findings, eIF2B5 depletion strongly increased phosphorylated AMPK in APCdef, but not in 229
APCres cells (Fig. 5d). We concluded that eIF2B5 depletion causes an APC-dependent 230
perturbation of cellular amino acid and nucleotide pools and of energy homeostasis. 231
232
Physiological eIF2B5 levels are required for tumourigenesis driven by loss of APC  233
To demonstrate the effects of eIF2B5 depletion in a genetically defined setting, we used 234
intestinal organoids [43, 44], generated from wild-type, VillinCreERApcfl/fl or 235
VillinCreERApcfl/flKrasG12D/+ mice and recombined them ex vivo by addition of 4-236
hydroxytamoxifen (4-OHT). Accordingly, MYC protein was induced in Cre-recombined 237
organoids relative to wild-type counterparts (Extended Data 6a). Doxycycline-inducible 238
eIF2B5 knockdown had no effect on the size of wild-type organoids, but dramatically reduced 239
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the growth of VillinCreERApcfl/fl and VillinCreERApcfl/flKrasG12D/+ organoids (Extended 240
Data 6b,c,d), arguing that eIF2B5 levels are critical for the growth of Apc-deleted organoids. 241
To validate our findings in a human setting, we used a panel of six patient-derived CRC 242
organoids. All five APC-mutated organoids showed a reduction in viability after eIF2B5 243
knockdown, whereas one APC wild-type organoid did not (Extended Data 6e,f,g).244
245
Since a complete Eif2b5 knockout is embryonically lethal [26], we characterized mice, in 246
which one Eif2b5 allele has been disrupted by integration of a gene-trap vector generating 247
Eif2b5+/tm1a(EUCOMM)Wtsi mice, hereafter designated Eif2b5+/- (Extended Data 7a). Eif2b5+/- mice 248
were born viable, at normal Mendelian ratios, were phenotypically indistinguishable from their 249
Eif2b5+/+ littermates and displayed normal intestinal tissue architecture with no changes in 250
cell size, survival, proliferation or differentiation (Extended Data 7b). Relative to wild-type 251
littermates, Eif2b5+/- mice displayed an approximately 50% reduction in eIF2B5 protein levels 252
in all analysed organs as well as in intestinal epithelial extracts (Fig. 6a and Extended Data 253
7c). These findings demonstrate that a 50% reduction in eIF2B5 is compatible with normal 254
organismal development and physiology. 255
To determine whether eIF2B5 levels are critical for colorectal tumour development driven by 256
Apc loss, we used mice carrying the conditional knockout Apc580s allele alone or in 257
combination with a conditional allele encoding oncogenic KrasG12D (VillinCreERApcfl/fl or 258
VillinCreERApcfl/flKrasG12D/+) [9, 45-47]. Apc deletion and Kras mutation increased eIF2B5 259
protein levels more than two-fold in small intestinal epithelial extracts, similar to what we 260
observed in human tumours (Fig. 6b). Histological staining confirmed reduced expression of 261
eIF2B5 in intestinal epithelia of Eif2b5+/- mice (Fig. 6c and Extended Data 7d). Levels of p-262
eIF2α were low in crypts in wild-type epithelia of small intestine and colon, whereas p-eIF2α263
was clearly detectable upon Apc deletion with or without activation of KrasG12D, consistent 264
with previous data that eIF2α phosphorylation increases during tumourigenesis (Fig. 6c and 265
Extended Data 7d) [28]. In both genetic backgrounds, p-eIF2α staining intensity was reduced 266
in Eif2b5+/- mice relative to Eif2b5+/+ counterparts, supporting the tissue culture data (Fig. 6c 267
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and Extended Data 7d). Loss of Apc led to massive tissue growth and a corresponding 268
increase in BrdU incorporation in the intestine of Eif2b5+/+ mice, which were further enhanced 269
upon simultaneous activation of oncogenic KrasG12D (Fig. 6c,d and Extended Data 7d,e). 270
These effects were significantly suppressed in the intestine of Eif2b5+/- mice, both in the 271
absence or presence of oncogenic KrasG12D (Fig. 6c,d and Extended Data 7d,e). Cleaved 272
caspase 3 increased robustly in VillinCreERApcfl/flEif2b5+/- and 273
VillinCreERApcfl/flKrasG12DEif2b5+/- compared to their Eif2b5+/+ counterparts (Fig. 6c,d and 274
Extended Data 7d,e). Loss of Apc increases MYC levels which are further enhanced by 275
introduction of a KrasG12D allele in Eif2b5+/+ mice [9, 48]. While corresponding Eif2b5+/- mice 276
show a further increase of MYC-positive cells, this did not reach statistical significance (Fig. 277
6c,d and Extended Data 7d,e). Therefore, the basic mechanism we describe also operates in 278
these cells; possibly, other ISR target proteins contribute to apoptosis induction aside from 279
MYC. 280
To analyse the impact of eIF2B5 on long-term survival in an Apc-deficient mouse model, we 281
crossed ApcMin/+ [49] mice to Eif2b5+/- animals. Relative to ApcMin/+ littermates, 282
ApcMin/+Eif2b5+/- animals had a significantly extended lifespan (median survival: 149 versus 283
127.5 days; Extended Data 8a,b). Importantly, organoids established from outgrowing 284
tumours of both genotypes revealed no difference in p-eIF2α  levels, protein synthesis rates 285
and polysome/sub-polysome ratio (Extended Data 8c-f). Furthermore, Eif2b5+/- tumours 286
restored eIF2B5 expression to approximately 70% of wild-type levels, indicating that 287
significant compensation had taken place during tumour evolution (Extended Data 8c,d). 288
Finally, acute deletion of both alleles of Eif2b5 in VillinCreERApcfl/fl mice decreased cell 289
proliferation and concomitantly increased MYC expression (Extended Data 8g,h), confirming 290
that targeting eIF2B5 can strongly affect tumour growth and raising the possibility that MYC 291
translation is largely independent of eIF2B5 in vivo.292
293
Targeting PKR and GCN2 opens a therapeutic window for APC loss-driven CRC294
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Since eIF2B5 cannot currently be targeted by small molecules, we tested whether inhibiting 295
eIF2α phosphorylation can achieve similar therapeutic efficacy. Four kinases (EIF2AK1-4) 296
phosphorylate eIF2α in response to distinct stresses [50]. Of these, HRI (heme-regulated 297
inhibitor; EIF2AK1) restricts globin translation in erythrocytes upon heme depletion, and 298
PERK (EIF2AK3) is activated in response to ER stress (see above). We therefore focused on 299
PKR (EIF2AK2), activated by double-stranded RNA, and on GCN2 (EIF2AK4), activated by 300
depletion of amino acids and uncharged tRNA pools [50]. Using antibodies that detect the 301
phosphorylated, active forms, we found that GCN2 and, to a lesser degree, PKR are 302
activated in APCdef compared to APCres cells (Fig. 7a). Intriguingly, MYC knockdown reduced 303
the levels of phosphorylated PKR and essentially abolished GCN2 phosphorylation (Fig. 7a 304
and Extended Data 9a). 305
306
Individual PKR or GCN2 knockdown suppressed the growth of APCdef cells to a variable 307
extent (Extended Data 9b). However, genetic depletion of either GCN2 or PKR did not 308
decrease p-eIF2α levels (Extended Data 9c), arguing that cells compensate for the lack of 309
either kinase during genetic suppression. To test whether an acute inhibition of either kinase 310
activity can mimic eIF2B5 depletion, we used small molecule inhibitors of GCN2 (A-92), PKR 311
(C16), or PERK (GSK2606414, hereafter GSK'414) [50]. GCN2 or PKR inhibition suppressed 312
the growth of APCdef cells, but had only minor effects on APCres cells (Fig. 7b). Both inhibitors 313
induced apoptosis in a dose-dependent manner in APCdef cells, but to a much lesser degree 314
in APCres cells, whereas inhibition of PERK had minor to no effects (Fig. 7c). In addition, A-92 315
reduced p-eIF2α levels, increased protein synthesis rates and induced MYC expression in 316
APCdef cells, thereby phenocopying the effects of eIF2B5 depletion (Fig. 7d,e). These effects 317
were less pronounced in response to PKR inhibition (Fig. 7f,g). Importantly, treatment of 318
VillinCreERApcfl/fl or VillinCreERApcfl/flKrasG12D/+ organoids with GCN2 or PKR inhibitors 319
suppressed organoid viability, whereas wild-type organoids were not affected (Fig. 8a,b). 320
Similarly, eight APC-mutated patient-derived organoid lines were sensitive to GCN2 and 321
PKR inhibition (Fig. 8c,d and Extended Data 10a). Furthermore, both inhibitors reduced p-322
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eIF2α levels in three human organoid lines, validating their on-target activity (Extended Data 323
10b). Finally, combining inhibitors with shRNAs that deplete the kinase not targeted by the 324
inhibitor led to additive effects in apoptosis induction (Extended Data 10c). We concluded 325
that primarily inhibition of GCN2, and to a lesser extent PKR, phenocopies eIF2B5 depletion 326
and suppresses the growth of APC-mutated CRC. 327
328
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Discussion329
Loss of APC increases global translation rates, leading to a MYC-dependent transcriptional 330
upregulation of multiple genes encoding proteins involved in mRNA translation. Using a 331
newly-established APC-deficient CRC cell line that can be induced to re-express full-length 332
APC, we uncovered a negative feedback loop which limits protein synthesis to prevent MYC-333
dependent apoptosis. We show that this is a vulnerability of APC-deficient CRC cells that can 334
be targeted using small molecules. 335
336
Specifically, we found that the survival of APC-deficient cells strictly depends on 337
physiological levels of the translation initiation factor eIF2B5. eIF2B5 depletion reduces the 338
initiation of mRNA translation leading to an ISR that involves a stress-related translation 339
program. In parallel, eIF2B5 depletion enhances MYC translation via a stress-responsive 340
IRES in the 5'-UTR of the MYC mRNA. Induction of apoptosis upon eIF2B5 depletion 341
depends on MYC upregulation; other proteins translated as part of the ISR may also 342
contribute. In culture, eIF2B5 depletion induces apoptosis selectively in APC-deficient cells 343
since loss of APC upregulates MYC mRNA levels [8]. Accordingly, Eif2b5+/- mice show a 344
normal development but a strongly impaired hyperproliferation in response to Apc loss 345
correlating with increased apoptosis. 346
347
The eIF2B complex binds tightly to eIF2 when eIF2α is phosphorylated [24], preventing 348
dephosphorylation of eIF2α. In tumour cells, a significant fraction of eIF2α is phosphorylated 349
and hence tightly bound to eIF2B. As a consequence, eIF2B5 depletion leads to increased 350
rather than decreased, overall protein synthesis rates. This increase, in combination with a 351
MYC-driven induction of genes encoding nucleotide biosynthesis enzymes, causes an 352
imbalance in amino acid and nucleotide pools and strains cellular energy resources, leading 353
to activation of AMPK upon eIF2B5 depletion in APC-deficient cells. Activation of AMPK is a 354
critical mediator of MYC-driven apoptosis in epithelial cells [51, 52], suggesting that it 355
contributes to MYC-dependent apoptosis upon eIF2B5 depletion. 356
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357
Deregulated protein synthesis and the perturbance of amino acid pools activate the GCN2 358
kinase, which binds uncharged tRNAs in response to decreased amino acid levels and 359
phosphorylates eIF2α [53]. Deregulation of MYC broadly stimulates RNA synthesis by all 360
three RNA polymerases [17], suggesting that GCN2 provides a negative feedback signal that 361
restricts MYC translation to couple MYC-driven RNA synthesis to the availability of amino 362
acids (Fig. 8e). This notion is supported by previous observations implicating GCN2 in the 363
control of MYC translation [54]. MYC also contributes to the activation of PKR and inhibition 364
of PKR partially mimics the phenotype of GCN2 inhibition. Importantly, small molecule 365
inhibitors of GCN2 and, to a lesser degree, of PKR phenocopies eIF2B5 depletion, arguing 366
that inhibitors of either kinase are valid tools for the therapy of APC-deficient CRC. Since 367
transcription of MYC is almost universally deregulated in human tumours, strategies that 368
disrupt the negative MYC/GCN2/eIF2α feedback loop to induce apoptosis may be broadly 369
applicable in human tumours. 370
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Figure legends 402
403
Figure 1: Restoration of APC expression suppresses translation and anchorage-independent 404
growth.405
(a) Immunoblot of SW480TetOnAPC cells after 48 h treatment with doxycycline (APCres) or 406
ethanol (APCdef), representative of three independent experiments with similar results. 407
(b) mRNA expression of APC in SW480TetOnAPC cells (96 h ethanol or doxycycline, 408
respectively) analysed via qPCR (n = 3 biologically independent experiments); unpaired, two-409
tailed t-test.410
(c) mRNA expression of WNT pathway target genes MYC, AXIN2, DKK1 in SW480TetOnAPC411
cells treated as described in (b) analysed via qPCR (n = 3 biologically independent 412
experiments); unpaired, two-tailed t-test.413
(d) RNA-sequencing followed by GSEA of gene expression changes in APCdef and APCres414
cells (48 h ethanol and doxycycline, respectively). Enrichment plots of indicated gene sets 415
are displayed (n = 3 biologically independent experiments). Calculation of the normalised 416
enrichment score (NES) is based on a weighted running sum statistic and computed as part 417
of the GSEA methodology [55]. A Kolmogorov-Smirnov test with 1,000 permutations was 418
used to calculate P values that were then corrected for multiple testing using the Benjamini-419
Hoechberg procedure (FDR). 420
(e) 35S-methionine labelling of APCdef and APCres cells (72 h doxycycline). Incorporated 421
radioactivity was measured by scintillation counting. Data show mean ± s.d. (n = 3 422
biologically independent experiments); unpaired, two-tailed t-test.423
(f) Cumulative growth curve of APCdef and APCres cells treated with doxycycline or ethanol, 424
respectively. Data show mean ± s.d. (n = 3 biologically independent experiments); unpaired, 425
two-tailed t-test.426
(g) Anchorage-independent growth of APCdef and APCres colonies. Colonies were grown over 427
ten days, with fresh ethanol or doxycycline added every third day. Representative colonies 428
are shown. Scale bars = 50 μM. 429
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(h) Quantification of size of colonies from (g). Data show mean ± s.d. of all colonies counted 430
(n = 29 for APCdef and n = 25 for APCres); unpaired, two-tailed t-test.431
(i) Quantification of number of colonies from (g). Data show mean ± s.d. (n = 3 biologically 432
independent experiments); unpaired, two-tailed t-test.433
Unprocessed immunoblots are shown in Source Data Figure 1. 434
435
Figure 2: APC-deficient CRC cells depend on physiological eIF2B5 levels. 436
(a) Plot documenting log2 fold change of all shRNAs included in the screen in APCres versus 437
APCdef cells (median of n = 3 biologically independent experiments) with five shRNAs 438
targeting EIF2B5 shown in colour. 439
(b) Crystal violet staining of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells 440
(six days ethanol and doxycycline, respectively), representative of three biologically 441
independent experiments with similar results. Cells were lentivirally infected with shRNAs 442
targeting EIF2B5 or luciferase (shCTR). 443
(c) Relative number of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells 444
(seven days ethanol or doxycycline, respectively). Cell numbers were determined by staining 445
with Hoechst and high-content microscopy imaging. Data show mean ± s.d. (n = 3 446
biologically independent experiments); unpaired, two-tailed t-test.447
(d) Immunoblot of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells (72 h 448
ethanol or doxycycline), representative of five independent experiments with similar results. 449
(e) EIF2B5 mRNA levels determined via qPCR from cells described in (d). Data show mean 450
± s.d. (n = 4 biologically independent experiments); unpaired, two-tailed t-test. 451
(f) Annexin V/PI FACS analysis of shCTR-transduced or eIF2B5-depleted APCdef and APCres452
cells (96 h ethanol or doxycycline, respectively). Data shown mean ± s.d. (n = 3 biologically 453
independent experiments); unpaired, two-tailed t-test.454
(g) Immunoblot of shCTR-transduced or eIF2B5-depleted HT29 and HCT116 cells, 455
representative of two independent experiments with similar results. Cells were lentivirally 456
infected with shRNAs targeting EIF2B5 or luciferase (shCTR). 457
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(h) Crystal violet staining of shCTR-transduced or eIF2B5-depleted HT29 and HCT116 cells, 458
representative of two independent experiments with similar results. 459
(i) eIF2B5 staining of human CRC tumour tissue and normal mucosa (representative image 460
of n = 10 biologically independent patients). Scale bars = 100 μm. 461
Unprocessed immunoblots are shown in Source Data Figure 2. 462
463
Figure 3: eIF2B5 controls translation initiation and limits global protein synthesis. 464
(a) Polysome profiling of shCTR-transduced and eIF2B5-depleted APCdef cells (72 h ethanol) 465
incubated with harringtonine for 0 s (left) and 180 s (right) before harvest. 40S, 60S, 80S 466
monosomal and polysomal fractions are indicated. Data (0 s harringtonine) are 467
representative of three independent experiments with similar results, 180 s harringtonine 468
assay was performed once. 469
(b) 35S-methionine labelling of shCTR-transduced and eIF2B5-depleted APCdef and APCres470
cells (72 h ethanol or doxycycline, respectively). Incorporated radioactivity was measured by 471
scintillation counting. Data show mean ± s.d. (n = 3 biologically independent experiments); 472
unpaired, two-tailed t-test. 473
(c) Total eIF2α and p-eIF2α S51 staining of human CRC tumour tissue and normal mucosa 474
(representative image of n = 10 biologically independent patients). Scale bars = 100 μm. 475
(d) Immunoblot of shCTR-transduced and eIF2B5-depleted APCdef and APCres cells (96 h 476
ethanol or doxycycline, respectively), representative of three independent experiments with 477
similar results. p-eIF2α S51 levels, relative to total eIF2α levels, are shown below the 478
immunoblot. 479
(e) Immunoprecipitation of eIF2α in shCTR-transduced or eIF2B5-depleted APCdef and 480
APCres cells (72 h ethanol or doxycycline, respectively). As input, 3% of lysate was loaded. 481
Proteins bound to eIF2α were detected by immunoblotting. Average levels of 482
immunoprecipitated PP1 relative to immunoprecipitated eIF2α levels, normalised to input, 483
are shown below (n = 2 biologically independent experiments). s.e. short exposition, l.e. long 484
exposition. 485
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(f) Immunoblot of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells treated as 486
described in (d), representative of three independent experiments with similar results. 487
(g) RNA-sequencing followed by GSEA of gene expression changes in shCTR-transduced or 488
eIF2B5-depleted APCdef cells. Enrichment plot of a Reactome gene set representing an 489
ATF4-dependent stress response is shown (n = 3 biologically independent experiments). 490
Statistical analysis was done as described in Fig. 1d. 491
(h) Immunoblot of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells treated as 492
described in (d), representative of three independent experiments with similar results. 493
Unprocessed immunoblots are shown in Source Data Figure 3. 494
495
Figure 4: Depletion of eIF2B5 causes MYC-driven apoptosis.496
(a) Immunoblot of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells (96 h 497
ethanol or doxycycline, respectively), representative of three independent experiments with 498
similar results. 499
(b) 35S-methionine pulse-labelling followed by immunoprecipitation with a MYC-specific 500
antibody or control IgG in shCTR-transduced or eIF2B5-depleted APCdef and APCres cells 501
(96 h ethanol or doxycycline, respectively). Protein synthesis inhibitor cycloheximide (CHX) 502
was used as control. Radio-labelled MYC was detected by autoradiography. The arrow 503
indicates the position of the specific MYC band. Average MYC levels are shown below the 504
panel (n = 3 biologically independent experiments). 505
(c) Immunoblot of cymarine-treated (100 nM, 24 h) shCTR-transduced or eIF2B5-depleted 506
APCdef and APCres cells (72 h ethanol or doxycycline, respectively), representative of two 507
independent experiments with similar results. DMSO was used as solvent control. 508
(d) Immunoblot of shCTR-transduced and eIF2B5-depleted APCdef and APCres cells (96 h 509
ethanol or doxycycline, respectively) upon MYC depletion, representative of two independent 510
experiments with similar results. siRNA transfections were carried out using siCTR as non-511
targeting control or siMYC for 72 h. 512
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(e) Annexin V/PI FACS of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells 513
treated as described in (d). Data show mean ± s.d. (n = 3 biologically independent 514
experiments), unpaired, two-tailed t-test.515
Unprocessed immunoblots are shown in Source Data Figure 4. 516
517
Figure 5: Depletion of eIF2B5 causes an imbalance in amino acid and nucleotide pools.518
(a) Mass spectrometric analysis of intracellular alanine, aspartate and glutamate levels in519
shCTR-transduced or eIF2B5-depleted APCdef and APCres cells upon MYC depletion. siRNA 520
transfections were carried out using siCTR as non-targeting control or siMYC for 72 h. 521
Relative measured peak area normalised to protein concentration and total amino acid levels 522
is shown. Peak area in APCdef cells transfected with siCTR was set to one. Data represent 523
mean + s.d. (n = 6 biologically independent experiments); unpaired, two-tailed t-test. 524
(b) MA plot of RNA-sequencing data of APCdef and APCres cells. Genes associated with 525
inosine monophosphate (IMP)/purine biosynthesis (GO:0006188) are highlighted in red 526
(n = 3 biologically independent experiments). 527
(c) Mass spectrometric analysis of intracellular nucleotide levels in shCTR-transduced and 528
eIF2B5-depleted APCdef and APCres cells treated as described in (a). Relative measured 529
peak area normalised to protein concentration is shown. Peak area in APCdef cells 530
transfected with siCTR was set to one. Data represent mean + s.d. (n = 5 biologically 531
independent experiments); unpaired, two-tailed t-test.532
(d) Immunoblot of shCTR-transduced or eIF2B5-depleted APCdef and APCres cells (96 h 533
ethanol or doxycycline, respectively), representative of two independent experiments with 534
similar results. As control for AMPK activation, cells were treated with AICAR (1 mM, 24 h). 535
Unprocessed immunoblots are shown in Source Data Figure 5. 536
537
Figure 6: Physiological eIF2B5 levels are required for tumourigenesis driven by loss of Apc.538
(a) Immunoblot of small intestine (s.i.), colon, liver, spleen and kidney from wild-type and 539
Eif2b5+/- mice. Analysis was done once with one mouse per genotype. 540
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(b) Immunoblot of intestinal epithelial extracts from mice of the indicated genotypes (left). 541
Each lane represents one separate mouse of the relevant group. Immunoblot was performed 542
once. Quantification of eIF2B5 protein levels, normalised to γ-tubulin (right). Data show mean 543
± s.d. (n = 3 biologically independent mice); one-tailed Mann-Whitney U test. 544
(c) Representative H&E-, eIF2B5-, p-eIF2α S51-, BrdU-, cleaved caspase 3-, and MYC-545
stained sections of small intestines from mice of the indicated genotypes. Mice were sampled 546
four and three days post-induction, as described in Methods. Red bars indicate the length of 547
the crypt (top panel). Scale bars = 100 μm. 548
(d) Graphs documenting the position of the highest BrdU-positive cell along the crypt-villus 549
axis (top panel), the total number of cells staining positive for BrdU per half crypt (top middle 550
panel), and the total number of cells per full crypt staining positive for cleaved caspase 3 551
(bottom middle panel) or MYC (bottom panel) in small intestines from mice of the indicated 552
genotypes. Data were scored in 25 crypts per mouse in at least three biologically 553
independent mice (n = 3 for highest BrdU-positive cell in wild-type and Eif2b5+/-, n = 5 for 554
highest BrdU-positive cell in VillinCreERApcfl/flEif2b5+/-, n = 5 for BrdU staining in 555
VillinCreERApcfl/flEif2b5+/-, n = 5 for cleaved caspase 3 staining in VillinCreERApcfl/flEif2b5+/- and556
VillinCreERApcfl/flKrasG12D/+Eif2b5+/-, n = 5 for MYC staining in Eif2b5+/-, VillinCreERApcfl/fl and 557
VillinCreERApcfl/flEif2b5+/- mice, n = 6 for all other stainings and genotypes). Data show mean 558
± s.e.m.; one-tailed Mann-Whitney U.559
Unprocessed immunoblots are shown in Source Data Figure 6. 560
561
Figure 7: Inhibition of PKR and GCN2 phenocopies eIF2B5 knockdown. 562
(a) Immunoblot of APCdef and APCres cells upon siRNA-mediated knockdown of MYC (96 h 563
ethanol or doxycycline, respectively), representative of two independent experiments with 564
similar results. siRNA transfections were carried out using siCTR as non-targeting control or 565
siMYC for 72 h. 566
(b) Crystal violet staining of APCdef and APCres cells (seven days ethanol or doxycycline, 567
respectively) in the presence of the following eIF2α kinase inhibitors for 96 h: A-92 (GCN2 568
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inhibitor), C16 (PKR inhibitor), GSK2606414 (PERK inhibitor, designated GSK‘414), 569
representative of three independent experiments with similar results. DMSO was used as 570
solvent control. 571
(c) Annexin V/PI FACS analysis of APCdef and APCres cells (five days ethanol or doxycycline, 572
respectively) treated with DMSO or inhibitors of GCN2 (A-92), PKR (C16), or PERK 573
(GSK'414) for 48 h at the indicated concentrations. Data show mean ± s.d. (n = 3 biologically 574
independent experiments); unpaired, two-tailed t-test.575
(d) Immunoblot of APCdef and APCres cells (72 h ethanol or doxycycline, respectively) after 576
DMSO or A-92 treatment (2 h), representative of two independent experiments with similar 577
results. p-eIF2α S51 levels, relative to total eIF2α levels, are shown below the immunoblot. 578
(e) 35S-methionine labelling of APCdef and APCres cells (96 h ethanol or doxycycline, 579
respectively) treated with DMSO or GCN2 inhibitor A-92 for 48 h. Incorporated radioactivity 580
was measured by scintillation counting. Data show mean ± s.e.m. (n = 3 biologically 581
independent experiments); unpaired, two-tailed t-test.582
(f) Immunoblots of APCdef and APCres cells (72 h ethanol or doxycycline, respectively) after 583
DMSO or C16 treatment (2 h), representative of two independent experiments with similar 584
results. p-eIF2α S51 levels, relative to total eIF2α levels, are shown below the immunoblot. 585
(g) 35S-methionine labelling of APCdef and APCres cells (96 h ethanol or doxycycline, 586
respectively) treated with DMSO or PKR inhibitor C16 for 48 h. Incorporated radioactivity was 587
measured by scintillation counting. Data show mean ± s.e.m. (n = 3 biologically independent 588
experiments); unpaired, two-tailed t-test.589
Unprocessed immunoblots are shown in Source Data Figure 7. 590
591
Figure 8: Targeting PKR and GCN2 activity opens a therapeutic window in APC-loss driven 592
CRC. 593
(a) Growth of murine organoids upon GCN2, PKR or PERK inhibition. Wild-type, 594
VillinCreERApcfl/fl or VillinCreERApcfl/flKrasG12D/+ organoids were grown for 72 h, then treated 595
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with A-92, C16 or GSK‘414 for 72 h. DMSO was used as solvent control. Representative 596
pictures of one organoid line of each genotype. Scale bars = 200 μM. 597
(b) Viability of organoids treated as described in (a) assessed using CellTiter Blue assay. 598
Data show mean of at least four technical replicates (black dots) of one line each, 599
representative of two biologically independent organoid lines per genotype and experiments 600
with similar results. 601
(c) Growth of one patient-derived organoid line treated with GCN2 (A-92) or PKR (C16) 602
inhibitors. T4 organoid line was grown for two days, and then treated with DMSO, A-92 or 603
C16 for 96 h at the indicated concentrations. Representative pictures from one experiment 604
are shown. Scale bars = 200 μM.  605
(d) Quantification of viability of eight patient-derived CRC organoid lines assessed by 606
CellTiter Blue assay. Organoids were treated as described in (c). Data show mean ± s.e.m 607
(n = 8 independent organoid lines; T1, T2, T3, T4, T5, T11, T13, T15); unpaired, two-tailed t-608
test.609
(e) Model explaining our findings. A MYC/GCN2/eIF2α negative feedback loop limits protein 610
synthesis to prevent MYC-dependent apoptosis in APC-deficient cells. In APC-proficient 611
cells, transcription of the MYC gene is strongly suppressed, hence the dependence on this 612
negative feedback loop is not shown. 613
614
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